Welcome to our dedicated page for Dexcom SEC filings (Ticker: DXCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DexCom, Inc. filings document formal disclosures for its continuous glucose monitoring and glucose biosensing business. Recent 8-K reports cover quarterly and annual financial results, preliminary financial outlook, revenue by geography, operating income, non-GAAP measures, and exhibits containing earnings releases.
Dexcom proxy and governance filings address annual meeting matters, board composition, committee assignments, director independence, executive compensation, pay-versus-performance disclosures, equity awards, indemnity arrangements, and leadership-related compensation terms. The filing record also reflects material-event reporting for board appointments and other governance changes.
Michael Brown plans to sell 1,700 shares of DXCM common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on or about July 15, 2026, with an aggregate market value of $126,514.00.
There are 385,872,977 common shares outstanding. Over the past three months, Brown sold 1,700 shares on May 15, 2026 for $101,847.00 and 1,700 shares on June 15, 2026 for $128,435.00.
Dexcom Inc. Executive Chair Kevin R. Sayer sold 26,756 shares of common stock in an open-market transaction at $72.00 per share. The sale was executed under a Rule 10b5-1 trading plan that Sayer adopted on February 18, 2026 to allow orderly dispositions of his holdings.
After the transaction, Sayer directly owns 355,726 Dexcom shares, which include 106,972 unvested restricted stock units scheduled to vest in tranches through March 8, 2028. The filing shows he retains a substantial equity position following this planned sale.
DexCom filed a Form 144 reporting a proposed sale of 26,756 shares of Common stock. The filing shows an associated value of $1,926,432.00 and names Kevin R. Sayer in the transaction details. The filing lists 07/06/2026 and indicates placement with Morgan Stanley Smith Barney LLC.
DexCom Inc. executive Michael Jon Brown, EVP and Chief Legal Compliance Officer, reported an open-market sale of 1,700 shares of common stock at $75.55 per share on June 15, 2026. After the sale, he directly holds 106,353 shares, including 74,753 unvested restricted stock units that vest over multiple dates through March 8, 2029. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025, indicating it was scheduled in advance as part of an orderly disposition program.
Dexcom Inc. director Mark G. Foletta reported indirect stock sales executed by The Foletta Family Trust under a pre-arranged Rule 10b5-1 trading plan. On June 15, 2026, the trust sold a total of 4,000 Dexcom common shares in open-market transactions at weighted average prices around $74 per share.
The filing shows two sale blocks: 3,801 shares at a weighted average price of $74.0991 and 199 shares at a weighted average price of $74.8187. Following the transactions, Foletta also reports holding 6,331 Dexcom shares directly.
Michael Brown submitted a Form 144 notice regarding a proposed sale of 1,700 shares of Common Stock. The filing lists the securities as Restricted Stock with an effective date of 03/08/2026 and shows Morgan Stanley Smith Barney LLC as the broker. The filing also records three recent sales of 1,700 shares each on 05/15/2026, 04/15/2026 and 03/16/2026 with transaction amounts of $101,847.00, $107,168.00 and $110,245.00, respectively.
Dexcom Inc. executive Jon Coleman reported open-market sales of company stock under a pre-arranged trading plan. On June 3, 2026, he sold 4,912 shares of common stock at $73.00 per share. On June 4, 2026, he sold an additional 4,911 shares at $74.13 per share.
These transactions, totaling 9,823 shares, were executed pursuant to a Rule 10b5-1 Plan adopted on March 4, 2026, which is designed to allow orderly, pre-scheduled dispositions. After these sales, Coleman directly held 95,450 shares of Dexcom common stock. A related disclosure notes that this number includes 95,450 unvested restricted stock units, consisting of 43,897 units granted March 8, 2026 vesting through March 8, 2029, and 51,553 units granted May 22, 2025 vesting through May 22, 2029. The filing shows no derivative positions remaining.
DXCM notice of proposed sale under Form 144: an affiliate lists 4911 shares of Common Stock as restricted stock to be sold 05/22/2026. The filing also records a sale of 4912 shares of Common Stock by Jon C. Coleman on 06/03/2026.